Kamira Maharaj
Overview
Explore the profile of Kamira Maharaj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gamal W, Goedhart N, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters F, et al.
Blood Adv
. 2025 Feb;
PMID: 39938006
An unmet clinical need in chronic lymphocytic leukemia (CLL) is emerging due to the rapidly expanding group of patients with double refractory (BTK- and Bcl2-inhibitor) disease. So far, autologous T-cell-based...
2.
Badal K, Monroe N, Mohamed A, Maniam A, Badal M, Maharaj K
J Cancer Educ
. 2024 Nov;
40(1):110.
PMID: 39546253
No abstract available.
3.
Badal K, Monroe N, Mohamed A, Maniam A, Badal M, Maharaj K
J Cancer Educ
. 2024 Sep;
40(1):102-109.
PMID: 39316342
Limited research exists on the effectiveness of cancer patient navigation (CPN) in limited-resource countries which are challenging for patients to navigate. The aim of this study was to report on...
4.
Handley K, Mehta S, Martin A, Biswas S, Maharaj K, Nagy M, et al.
Gynecol Oncol
. 2023 Apr;
173:114-121.
PMID: 37121178
Objective: To demonstrate that shared antibody responses in endometriosis and endometriosis-associated ovarian cancer spontaneously antagonize malignant progression and can be leveraged to develop future immunotherapies. Methods: B cells from cyopreserved...
5.
Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J
Front Immunol
. 2022 Aug;
13:943354.
PMID: 35979372
Regulatory T cells (Tregs) are responsible for maintaining immune homeostasis by controlling immune responses. They can be characterized by concomitant expression of FoxP3, CD25 and inhibitory receptors such as PD-1...
6.
Maharaj K, Powers J, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, et al.
Front Immunol
. 2020 Dec;
11:590072.
PMID: 33329575
Development of chronic lymphocytic leukemia (CLL) is associated with severe immune dysfunction. T-cell exhaustion, immune checkpoint upregulation, and increase of regulatory T cells contribute to an immunosuppressive tumor microenvironment. As...
7.
Maharaj K, Powers J, Achille A, Mediavilla-Varela M, Gamal W, Burger K, et al.
Blood Adv
. 2020 Jul;
4(13):3072-3084.
PMID: 32634240
The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic...
8.
Maharaj K, Powers J, Achille A, Deng S, Fonseca R, Pabon-Saldana M, et al.
Blood Adv
. 2018 Nov;
2(21):3012-3024.
PMID: 30425065
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist...
9.
Maharaj K, Sahakian E, Pinilla-Ibarz J
Blood Adv
. 2018 Jan;
1(21):1867-1875.
PMID: 29296833
Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as ibrutinib and idelalisib, are known to show activity in chronic lymphocytic leukemia (CLL) via their direct effects on...
10.
Sahakian E, Chen J, Powers J, Chen X, Maharaj K, Deng S, et al.
J Leukoc Biol
. 2017 May;
102(2):475-486.
PMID: 28550123
Epigenetic changes in chromatin structure have been recently associated with the deregulated expression of critical genes in normal and malignant processes. HDAC11, the newest member of the HDAC family of...